APEN:NSD-Apollo Endosurgery Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 5.60

Change

-0.21 (-3.61)%

Market Cap

USD 0.23B

Volume

0.27M

Avg Analyst Target

USD 13.60 (+142.86%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Apollo Endosurgery Inc (APEN) Stock Analysis:
Based on the Apollo Endosurgery Inc stock forecasts from 5 analysts, the average analyst target price for Apollo Endosurgery Inc is USD 13.60 over the next 12 months. Apollo Endosurgery Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apollo Endosurgery Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Apollo Endosurgery Inc’s stock price was USD 5.60. Apollo Endosurgery Inc’s stock price has changed by -0.65% over the past week, -2.65% over the past month and +40.00% over the last year.

About

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to p ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-20 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-0.59 (-0.14%)

USD43.36B 84.37 117.62
ALGN Align Technology Inc

-6.88 (-1.38%)

USD38.60B 52.77 48.05
PODD Insulet Corporation

-2.70 (-1.15%)

USD16.21B 2,208.27 199.97
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed Inc

+0.73 (+0.24%)

USD13.74B 92.73 46.15
BRKR Bruker Corporation

-1.22 (-1.78%)

USD10.73B 39.93 25.78
TNDM Tandem Diabetes Care Inc

-0.14 (-0.11%)

USD7.90B 366.78 187.52
SWAV ShockWave Medical Inc

-4.05 (-2.80%)

USD5.90B N/A N/A
IART Integra LifeSciences Holdings ..

-0.36 (-0.54%)

USD5.77B 26.80 17.89
LIVN LivaNova PLC

-1.40 (-1.68%)

USD4.51B 77.40 N/A

ETFs Containing APEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.57% 4% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.57% 4% F 4% F
Trailing 12 Months  
Capital Gain 40.00% 94% A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.00% 94% A 89% B+
Trailing 5 Years  
Capital Gain -61.95% 27% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.95% 27% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain 50.60% 74% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.60% 74% C 85% B
Risk Return Profile  
Volatility (Standard Deviation) 157.99% 17% F 9% F
Risk Adjusted Return 32.03% 43% F 49% F
Market Capitalization 0.23B 53% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 138.96 1% F 1% F
Price / Cash Flow Ratio -11.02 64% D 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -344.38% 8% F 11% F
Return on Invested Capital -26.76% 44% F 25% F
Return on Assets -13.79% 48% F 26% F
Debt to Equity Ratio 838.08% 3% F 2% F
Technical Ratios  
Short Ratio 2.60 53% F 46% F
Short Percent 2.73% 63% D 49% F
Beta 2.20 9% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector